Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) were given to 63.88% of patients, angiotensin receptor–neprilysin inhibitors (ARNi) were prescribed to 11.11% of patients, and mineralocorticoid receptor antagonists (MRA) were used in 48.14% of cases, highlighting their importance in managing heart failure and reducing hospitalizations [25]. The gene discussed is NR3C2; the disease is heart failure.